Clopivas Tablets (Generic Plavix) - Active Ingredient And Chemical structure
The active ingredient contained in Clopivas Tablets is Clopidogrel Bisulfate. Clopidogrel bisulfate is a white to off-white powder which is practically insoluble in water. The structure is shown below
Clopivas Tablets (Clopidogrel) - Preparations
Clopivas Tablets are available as oral tablets of 75 mg . Each film coated tablet contains 75 mg of Clopidogrel Bisulfate
Generic Forms and Brand names of Plavix (Clopidogrel Bisulfate)
Clopivas manufactured by Cipla Ltd., India is an effective treatment for Acute Coronary Syndrome, Myocardial Infarction, Recent Stroke or Established Peripheral Arterial Disease. Generic Plavix which has the active ingredient Clopidogrel Bisulfate is also sold as Plagril tablets and under various other brand names.
Clopivas Tablets - Storage Requirements
Clopivas Tablets are to be stored at room temperature (15°C to 30°C) in a cool and dry place. Store away from heat, moisture, and light. Keep out of reach of children and pets.
Clopivas Tablets - Uses
Clopivas (Clopidogrel) is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y12 class of adenosine diphosphate (ADP) receptors on platelets. Clopivas used to treat:
Acute coronary syndrome
Patients with non-ST-segment elevation ACS
Patients with ST-elevation myocardial infarction (STEMI)
Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease.
Clopivas Tablets (Clopidogrel Bisulfate) - Dosage
Clopivas Tablets can be administered with or without food. The dosing for Clopivas Tablets is as follows:
Acute coronary syndrome
-For patients with Non-ST-segment elevation ACS (UA/NSTEMI): Initiate Clopivas (clopidogrel) with a single 300 mg oral loading dose followed by 75 mg once daily, in combination with aspirin (75-325 mg once daily)
-For patients with STEMI: The recommended dose of Clopivas (clopidogrel) is 75 mg once daily, in combination with aspirin (75-325 mg once daily), with or without a loading dose and with or without thrombolytics
Recent MI, recent stroke, or established peripheral arterial disease (PAD):The recommended dose of Clopivas is 75 mg once daily orally, with or without food.
Clopivas Tablets (Clopidogrel Bisulfate) - Contraindications
Clopivas Tablets is contraindicated in patients with active pathological bleeding such as peptic ulcer or intracranial hemorrhage. Clopivas Tablets are also contraindicated in patients with hypersensitivity to Clopidogrel Bisulfate or any any inactive ingredient of the product.
Side Effects Of Clopivas Tablets (Clopidogrel Bisulfate)
Clopivas is generally well tolerated. Side effects of Clopivas Tablets (Clopidogrel) that have been reported include bleeding, including life-threatening and fatal bleeding, thrombotic thrombocytopenic purpura (TTP), gastrointestinal hemorrhage, pruritus, chest pain, headache, upper respiratory tract infection, rash, edema and influenza like symptoms.
